How should I taper and discontinue tandospirone (60 mg daily) after three months of use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

坦度螺酮停药方案

对于服用坦度螺酮60mg/天持续3个月的患者,应采用逐步递减的停药方法,建议每2周减少10-20%的当前剂量,总停药时间至少需要2-3个月,以避免戒断症状。

推荐的停药方案

虽然没有坦度螺酮特定的停药指南,但基于抗抑郁药和苯二氮䓬类药物的停药原则123,应遵循以下方案:

初始减量阶段(第1-4周)

  • 从60mg开始,每2周减少10mg
  • 第1-2周:50mg/天(分3次服用)
  • 第3-4周:40mg/天(分3次服用)

中期减量阶段(第5-8周)

  • 减量速度放缓,每2-4周减少5-10mg
  • 第5-6周:30mg/天
  • 第7-8周:20mg/天

末期减量阶段(第9-12周)

  • 最后阶段需要更小幅度的减量23
  • 第9-10周:15mg/天
  • 第11-12周:10mg/天
  • 第13-14周:5mg/天
  • 然后停药

重要注意事项

戒断症状的识别

服用坦度螺酮3个月已形成一定程度的生理依赖。停药过程中可能出现:

  • 焦虑症状反弹
  • 失眠、烦躁
  • 头晕、恶心
  • 情绪不稳定

调整停药速度的指征

如果出现明显戒断症状,应立即暂停减量或回到上一个耐受剂量13:

  • 焦虑明显加重
  • 出现新的躯体症状
  • 功能明显受损

高危患者的特殊考虑

以下情况需要更缓慢的停药(可能需要4-6个月)13:

  • 既往有停药困难史
  • 合并使用其他精神科药物
  • 基础焦虑障碍严重
  • 老年患者4

辅助措施

药物辅助

如出现戒断症状,可短期使用5:

  • 曲唑酮:用于失眠和焦虑
  • 加巴喷丁:缓解焦虑和躯体不适
  • 米氮平:改善睡眠和情绪

非药物支持

  • 每2-4周随访评估1
  • 认知行为治疗
  • 放松训练和正念减压

关键警告

绝对避免突然停药13。坦度螺酮作为5-HT1A部分激动剂4,突然停药可能导致严重的戒断反应和焦虑症状反弹。

区分戒断症状与疾病复发51:

  • 戒断症状通常在减量后数天内出现,持续1-2周
  • 疾病复发通常在停药后数周至数月出现,症状持续时间更长

研究显示坦度螺酮60mg/天治疗广泛性焦虑障碍有效6,但也提示高剂量可能增加不良反应。因此停药过程需要谨慎,个别患者可能需要更长的停药时间(3-6个月),特别是如果在减量过程中出现明显不适。

References

Research

Stopping antidepressants safely.

African journal of primary health care & family medicine, 2026

Research

Stopping antidepressants: when and how.

Australian prescriber, 2026

Research

5-HT1A Partial Agonist Tandospirone for Behavioral and Psychological Symptoms in Oldest-old Patients with Dementia at a Special Elderly Nursing Home.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.